3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
303
Carcinoma, Non-Small-Cell Lung
240
Prostatic Neoplasms
196
Neoplasms
190
Lung Neoplasms
149
Multiple Myeloma
141
Neoplasm Metastasis
110
Colorectal Neoplasms
104
Melanoma
97
Ovarian Neoplasms
90
Leukemia, Myeloid, Acute
82
Pancreatic Neoplasms
76
Lymphoma
76
Leukemia, Lymphocytic, Chronic, B-Cell
71
Brain Neoplasms
69
Carcinoma, Renal Cell
67
Squamous Cell Carcinoma of Head and Neck
62
Lymphoma, Non-Hodgkin
62
Carcinoma, Hepatocellular
61
Hematologic Neoplasms
60
Urinary Bladder Neoplasms
58
Head and Neck Neoplasms
56
Triple Negative Breast Neoplasms
55
Recurrence
54
Glioblastoma
53
Uterine Cervical Neoplasms
51
Lymphoma, Follicular
51
Endometrial Neoplasms
50
Stomach Neoplasms
46
Sarcoma
46
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
90 days
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled